Affiliation
University of Manchester Manchester Cancer Research CentreIssue Date
2018
Metadata
Show full item recordAbstract
Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al.Citation
Rebello RJ, Oing C, Gillessen S, Bristow RG. TP53 and prognosis in mCRPC survival: biology or coincidence. Clin Cancer Res. 2019.Journal
Clincal Cancer ResearchDOI
10.1158/1078-0432.CCR-18-3401PubMed ID
30610102Additional Links
https://dx.doi.org/10.1158/1078-0432.CCR-18-3401Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-18-3401
Scopus Count
Collections
Related articles
- <i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
- Authors: De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY
- Issue date: 2019 Mar 15
- AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
- Authors: Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM
- Issue date: 2017 Nov
- TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
- Authors: Chapman L, Ledet EM, Barata PC, Cotogno P, Manogue C, Moses M, Christensen BR, Steinwald P, Ranasinghe L, Layton JL, Lewis BE, Sartor O
- Issue date: 2020 Apr
- Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
- Authors: Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, Perakis S, Gormley M, Patel J, Li W, Geigl JB, Smirnov D, Heitzer E, Gross M, Speicher MR
- Issue date: 2018 Sep 1
- Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
- Authors: Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Agarwal N, Sartor O, Barata PC
- Issue date: 2020